Akums Drugs and Pharmaceuticals (NSE:AKUMS) EV-to-EBIT : 29.71 (As of May. 29, 2025)

Akums Drugs and Pharmaceuticals EV-to-EBIT Chart

Akums Drugs and Pharmaceuticals Quarterly Data
	Mar21	Mar22	Mar23	Sep23	Dec23	Mar24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial				-	-	80.96	54.53	17.76

Competitive Comparison of Akums Drugs and Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akums Drugs and Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Akums Drugs and Pharmaceuticals's EV-to-EBIT falls into.

Akums Drugs and Pharmaceuticals EV-to-EBIT Calculation

Akums Drugs and Pharmaceuticals's EV-to-EBIT for today is calculated as:

Akums Drugs and Pharmaceuticals's current Enterprise Value is ₹83,004 Mil.
Akums Drugs and Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,794 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals  (NSE:AKUMS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Akums Drugs and Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Akums Drugs and Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2025 was ₹67,250 Mil.
Akums Drugs and Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,794 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Akums Drugs and Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Akums Drugs and Pharmaceuticals Business Description